# EDGAR Filing Document

**Accession Number:** 0001752828
**File Stem:** 0001493152-26-027132
**Filing Date:** 2026-6
**Character Count:** 23750
**Document Hash:** 3176b2a92a2d4e465d2e4114e74745e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-027132.hdr.sgml**: 20260603

**ACCESSION NUMBER**: 0001493152-26-027132

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260529

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260603

**DATE AS OF CHANGE**: 20260603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celularity Inc
- **CENTRAL INDEX KEY:** 0001752828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831702591
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38914
- **FILM NUMBER:** 261062104

**BUSINESS ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (908) 768-2170

**MAIL ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GX Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180912

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 29, 2026**

**Celularity Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38914** | **83-1702591** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **170 Park Ave**<br> **Florham Park, New Jersey** | **07932** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(908) 768-2170**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, $0.0001 par value per share | CELU | The Nasdaq Stock Market LLC |
| Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per share | CELUW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 29, 2026, Celularity Inc. ("Celularity") appointed Rick Gonzalez as Chief Commercial Officer of Celularity. Mr. Gonzalez will report directly to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman and Chief Executive Officer.

Celularity has not entered into a definitive employment agreement with Mr. Gonzalez in connection with his appointment. Celularity will disclose the material terms of any definitive compensatory arrangement with Mr. Gonzalez in a subsequent filing with the Securities and Exchange Commission, as required.

There are no family relationships between Mr. Gonzalez and any director or executive officer of Celularity. There are no arrangements or understandings between Mr. Gonzalez and any other person pursuant to which he was appointed as Chief Commercial Officer. Mr. Gonzalez is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

**Item 7.01. Regulation FD Disclosure.**

On June 3, 2026, Celularity issued a press release announcing the appointment of Mr. Gonzalez as Chief Commercial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Also on June 3, 2026, Celularity made available a letter to shareholders from Dr. Hariri, providing an update on Celularity's strategic focus, including its focus on longevity, regenerative medicine and the preservation of human performance, its commercial opportunity for cenplacel-L, its Lifebank cellular banking platform, and the appointment of Mr. Gonzalez as Chief Commercial Officer. A copy of the shareholder letter is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| 99.1 | [Press release issued by Celularity Inc. on June 3, 2026.](ex99-1.htm) |
| 99.2 | [Letter to Shareholders from Robert J. Hariri, MD, PhD, Chairman and CEO, dated June 3, 2023](ex99-2.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CELULARITY INC**. | **CELULARITY INC**. |
| Dated: June 3, 2026 |  |  |
|  | By: | */s/ John Sprague* |
|  | Name: | John Sprague |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Celularity Appoints Rick Gonzalez as Chief Commercial Officer**

● **Appointment supports Celularity's focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank** 

FLORHAM PARK, NJ, June 3, 2026 (GLOBE NEWSWIRE), Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder.

"Rick's appointment comes at an important time for Celularity as we continue to advance our revenue-generating strategy and expand the reach of our regenerative medicine platform," said Robert J. Hariri. "Celularity was founded on the belief that the placenta represents a powerful biological resource with the potential to transform medicine at global scale. As physician and patient interest in cellular medicine continues to grow, we believe Rick's experience building commercial organizations and executing disciplined growth strategies across complex healthcare markets will be important as we seek to expand responsible access to cenplacel-L, enhance our Lifebank offering, and translate Celularity's science into long-term value for physicians, patients, families and shareholders.

Mr. Gonzalez brings more than two decades of executive leadership experience across biotechnology, medical technology, precision medicine and digital health. Most recently, he served as Chief Commercial Officer of Alume Biosciences, where he led global commercialization strategy for a clinical-stage surgical visualization platform, including pricing, reimbursement, market access and launch readiness. He previously served as President, Chief Executive Officer and Director of Navidea Biopharmaceuticals, where he led commercialization of a precision diagnostic platform and drove 2.5x year-over-year revenue growth, and as Senior Vice President, Global Operations at Spectrum Pharmaceuticals, where he helped scale global revenue from $7.7 million to approximately $300 million through international expansion and commercialization of specialty therapies. Earlier in his career, Mr. Gonzalez held leadership roles at Abraxis, Genzyme, Corixa, Ligand and Roche.

Cenplacel-L, clinically investigated as PDA-001 and PDA-002, is Celularity's most mature placental-derived allogeneic cell therapy asset. The program reflects more than two decades of research by Celularity into the unique biological properties of postpartum placental cells. Celularity believes cenplacel-L has the potential to play an important role in the emerging global market for stem-cell and regenerative cellular therapies, particularly in jurisdictions where regulatory frameworks permit physician-directed access to such therapies.

The Company is seeing demand from physicians seeking access to high-quality, responsibly manufactured stem-cell therapies for appropriate patients in permissive markets. Since making cenplacel-L available to qualified physicians for investigational use in such jurisdictions, Celularity believes this early commercial traction supports the Company's decision to strengthen its commercial leadership with the appointment of Mr. Gonzalez and the continued build-out of commercial capabilities designed to support appropriate physician engagement, education and market development.

Mr. Gonzalez will also lead expansion of Celularity's Lifebank product offering for expectant parents and adults who wish to bank their own cells for potential future use. Lifebank generated sales in 2025 that reflected continued interest in cellular banking and its role in Celularity's broader longevity and regenerative medicine strategy. Celularity believes Lifebank is a natural extension of that strategy, providing individuals and families with an opportunity to preserve valuable cellular material at a time when interest in proactive health, cellular medicine and future therapeutic optionality continues to grow. Under Mr. Gonzalez's leadership, Celularity intends to strengthen commercial education around Lifebank, expand engagement with physicians and other healthcare providers, and broaden awareness among consumers seeking to preserve biological resources that may support future advances in regenerative medicine and human performance.

"I am honored to join Celularity at such a pivotal point in the Company's evolution," said Mr. Gonzalez. "Celularity has a differentiated foundation in placental-derived cellular therapy, a near-term commercial opportunity with cenplacel-L, the Lifebank cellular banking platform, and a broader mission that aligns with the growing demand for longevity and regenerative medicine. My focus will be on building disciplined commercial infrastructure, strengthening physician engagement, aligning cross-functional execution, and helping translate Celularity's scientific and manufacturing capabilities into sustainable commercial growth. I look forward to working with the team to expand access responsibly, support physicians and patients, and create long-term value for the Company and its stakeholders."

Celularity believes the next phase of regenerative medicine will be defined not only by demand for innovative cellular therapies, but also by manufacturing rigor, quality systems, regulatory discipline and clinically responsible access. The Company's current manufacturing infrastructure and existing inventory position it to support anticipated demand for cenplacel-L while maintaining the quality standards and manufacturing discipline central to Celularity's platform.

**About Celularity**

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta's unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.

For more information, please visit <u>www.celularity.com</u>.

**Forward Looking Statements**

This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding Celularity's commercial strategy, leadership appointments, longevity strategy, product opportunities, physician demand, responsible access, market expansion, Lifebank, cellular banking, future therapeutic optionality, revenue generation, growth prospects, manufacturing capabilities, anticipated demand, participating centers, repeat physician utilization, patient cohorts, and anticipated value creation. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks described in Celularity's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Celularity undertakes no obligation to update any forward-looking statements, except as required by law.

Carlos Ramirez

SVP, Investor Relations

Celularity Inc.<br> <u>Carlos.ramirez@celularity.com</u>

## Exhibit 99.2

**Exhibit 99.2**

Dear Fellow Shareholders,

I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress. At the same time, we recognize that the broader biotechnology sector, and cellular therapy companies in particular, continue to operate in a highly selective and challenging capital markets environment. Celularity's leadership has taken important steps to sharpen our strategic focus, strengthen our financial position and enable Celularity to pursue the opportunities we believe are most closely aligned with our founding vision. These actions are intended to streamline our business and concentrate resources where we believe we can create durable long-term value.

As previously <u>announced</u>, we completed a transaction with NexGel, Inc. to out-license the commercial assets of our biomaterials business for consideration of up to $30 million, whereupon through strategic structuring, we eliminated certain of our recorded liabilities by nearly $13 million. The rationale for the transaction was straightforward. The biomaterials business generated meaningful revenue during our ownership and supported the treatment of thousands of patients, but these assets no longer represent the central focus of our long-term strategy. In short, the transaction enabled us to simplify our operating structure and redirect attention and resources toward our core placental-derived cellular therapy programs in the field of longevity and age-related disease.

Celularity was founded on the belief that the placenta represents a powerful and ethical biological resource with the potential to transform medicine on a global scale. Together with Peter Diamandis, M.D., one of the leading voices in the global longevity and exponential technology movements, I launched Celularity around a shared conviction: that placental-derived cellular therapies could play an anchoring role in extending human health span, addressing age-related disease and improving human performance. That vision continues to guide our strategy today.

Celularity sits at a unique intersection of regenerative medicine, immunology and aging biology. Our technologies are designed to harness the intrinsic biological properties of placental cells to address inflammation and the degenerative changes associated with aging. As global interest in longevity, cellular medicine, and regenerative therapies continues to expand, we believe Celularity is uniquely positioned to be a leader in this exciting area of medical innovation.

Central to our renewed focus is our most mature cell therapy product, cenplacel-L. Cenplacel-L is a placental-derived allogeneic cell therapy in the broader category of stem-cell and regenerative medicine, developed from postpartum placental tissue and designed to deliver the regenerative, immunomodulatory and anti-inflammatory potential of placental cells and reflects more than two decades of research by Celularity and its predecessor company, Celgene Cellular Therapeutics.

We believe cenplacel-L has the potential to play an important role in the emerging global market for stem-cell and regenerative cellular therapies, particularly in jurisdictions where regulatory frameworks permit physician-directed access to such therapies. These markets offer Celularity the opportunity to generate early commercial activity and build real-world clinical experience while continuing to evaluate opportunities to advance cenplacel-L through traditional regulatory pathways.

We are excited that physician interest in cenplacel-L has been strong. We are seeing demand from physicians seeking access to high-quality, responsibly manufactured placental-derived cellular therapies for appropriate patients in permissive markets. This demand includes interest from our affiliate partners at Fountain Life, whose physician network, focused on longevity, performance, and proactive health, has a mission closely aligned with Celularity. We believe the next phase of regenerative medicine will be defined not only by physician demand, but by manufacturing rigor, quality systems, regulatory discipline, and clinically responsible access. We believe these are areas where Celularity is well-positioned to differentiate.

Since emerging as a spin-off from Celgene at the end of 2017, Celularity has distinguished itself from other cellular medicine companies through our ability to generate revenues from placental biomaterials, CDMO and biobanking services, and the sale of cenplacel-L. While still early in the commercialization process, we believe growth in cenplacel-L revenues in 2026 will be driven principally by increasing physician participation and patient adoption in Florida, where the evolving regulatory framework and our collaboration with Fountain Life are helping to create an important initial market for placental-derived cellular therapies. We believe this market can provide a meaningful foundation for early commercial growth while also contributing valuable real-world clinical experience. Importantly, our current manufacturing infrastructure and existing inventory position us well to support anticipated demand, and we believe we have abundant capacity to meet expected growth while maintaining the quality standards and manufacturing discipline central to Celularity's platform. As we scale, we intend to report on key metrics such as the number of participating centers, repeat physician utilization, and patient cohorts to provide greater transparency into the trajectory of this emerging commercial opportunity.

As Celularity enters this next phase, we are pleased to welcome Rick Gonzalez as Chief Commercial Officer. Rick will be responsible for leading Celularity's commercial strategy, with a focus on expanding physician access to cenplacel-L and related Celularity products. His leadership will be critical as we seek to translate growing physician interest into a disciplined and scalable commercial model. One that broadens access while maintaining the quality, manufacturing rigor, and scientific integrity central to Celularity's platform.

Cenplacel-L also remains an important part of Celularity's longer-term clinical strategy. Previously investigated as PDA-001 and PDA-002, cenplacel-L has been studied across multiple indications, and we continue to evaluate opportunities to return this program to the clinic in the United States in areas where placental-derived cellular therapy may address significant unmet medical need.

We are also continuing to explore the potential of our natural killer cell program, CYNK-001, including its potential application as a senoblative therapy. Senescent cells accumulate with age and contribute to tissue dysfunction, degenerative disease and declining physiological performance. The ability to selectively eliminate these cells represents an emerging approach to addressing biological mechanisms that influence aging and health span. Together, we believe cenplacel-L and CYNK-001 represent complementary pillars of a differentiated, placenta-derived longevity platform designed to address both the consequences and underlying biological drivers of age-related decline.

While we are encouraged by the opportunities ahead, we remain realistic about the challenges facing Celularity. Like many companies advancing novel cellular therapies, we operate in a demanding capital environment. Our existing residual debt obligations and capital constraints require discipline and careful execution. In parallel, we are actively evaluating opportunities to support the business through strategic partnerships, non-dilutive sources of capital, and disciplined geographic expansion in markets where the regulatory environment and physician demand may enable responsible near-term commercialization. The actions we are taking, including the NexGel transaction and our renewed focus on cell therapy in longevity, are intended to strengthen Celularity's financial position and concentrate our resources on the programs where we believe our science, manufacturing capabilities and strategic relationships can create the greatest long-term value.

Celularity is entering a new phase of focused execution. With a more streamlined operating structure, a differentiated placental-derived cellular therapy platform, growing physician interest in cenplacel-L, and the addition of experienced commercial leadership to expand physician access, we believe Celularity is well-positioned to pursue meaningful near-term commercial opportunities while continuing to advance its broader mission in longevity, regenerative medicine, and cellular therapy to preserve human performance. Thank you for your continued support and confidence in Celularity.

Sincerely,

Robert J. Hariri, M.D., Ph.D.

Founder, Chairman and Chief Executive Officer

Celularity Inc.